MedPath

Study Identifies Key Factors for Long-Term Weight Loss with GLP-1 Medications

Cleveland Clinic study on GLP-1 receptor agonist medications like semaglutide and liraglutide finds semaglutide more effective for long-term weight loss, especially for obesity treatment. Higher doses and persistence with medication significantly impact weight reduction. Women and those with higher initial BMI more likely to achieve 10% weight loss.


Reference News

Real-world data reveals factors associated with long-term weight loss in obesity

Cleveland Clinic study in JAMA Network Open identifies factors impacting long-term weight loss with semaglutide or liraglutide, finding that persistence, medication type, and treatment indication significantly affect weight reduction outcomes.

Cleveland Clinic Study IDs Factors Behind Long-Term Weight Loss with GLP-1 RA Drugs

Cleveland Clinic study identifies factors impacting long-term weight loss with semaglutide or liraglutide, including medication agent, dosage, treatment indication, and persistence. Semaglutide showed greater weight reduction than liraglutide, with higher doses and obesity treatment leading to more significant losses. Persistence with medication was crucial, with 61% of persistent semaglutide users for obesity achieving 10% weight reduction.

Study Identifies Key Factors for Long-Term Weight Loss with GLP-1 Medications

Cleveland Clinic study on GLP-1 receptor agonist medications like semaglutide and liraglutide finds semaglutide more effective for long-term weight loss, especially for obesity treatment. Higher doses and persistence with medication significantly impact weight reduction. Women and those with higher initial BMI more likely to achieve 10% weight loss.

© Copyright 2025. All Rights Reserved by MedPath